brexpiprazole šŸ¶ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychotropics, phenylpiperazine derivatives 5014 913611-97-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • brexpiprazole
  • rexulti
  • OPC-34712
  • OPC 34712
an atypical antipsychotic the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors
  • Molecular weight: 433.57
  • Formula: C25H27N3O2S
  • CLOGP: 4.90
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 44.81
  • ALOGS: -5.28
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 1.46 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.34 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 54.37 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 1 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
July 27, 2018 EMA OTSUKA PHARM CO LTD
July 10, 2015 FDA OTSUKA PHARM CO LTD
Jan. 19, 2018 PMDA Otsuka Pharmaceutical Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 530.32 23.50 134 6518 9012 63473358
Schizoaffective disorder 437.86 23.50 96 6556 3466 63478904
Weight increased 357.22 23.50 260 6392 260532 63221838
Tardive dyskinesia 350.17 23.50 95 6557 8407 63473963
Drug level increased 258.19 23.50 95 6557 22641 63459729
Electrocardiogram QT prolonged 204.13 23.50 107 6545 59423 63422947
Product use in unapproved indication 163.28 23.50 141 6511 178939 63303431
Off label use 125.06 23.50 239 6413 674223 62808147
Restlessness 118.41 23.50 59 6593 29394 63452976
Tremor 118.08 23.50 103 6549 132136 63350234
Hallucination, auditory 110.99 23.50 44 6608 12780 63469590
Suicidal ideation 95.71 23.50 67 6585 62354 63420016
Mania 95.18 23.50 39 6613 12328 63470042
Drug interaction 91.38 23.50 116 6536 229015 63253355
Extrapyramidal disorder 82.59 23.50 36 6616 13248 63469122
Oculogyric crisis 79.12 23.50 21 6631 1700 63480670
Product administered to patient of inappropriate age 74.15 23.50 23 6629 3245 63479125
Inability to afford medication 72.67 23.50 21 6631 2326 63480044
Discoloured vomit 71.54 23.50 17 6635 877 63481493
Sinus rhythm 61.90 23.50 15 6637 841 63481529
Anxiety 52.64 23.50 87 6565 217454 63264916
Therapy cessation 49.71 23.50 34 6618 30423 63451947
Depression 48.08 23.50 79 6573 196413 63285957
Collagen-vascular disease 44.81 23.50 8 6644 96 63482274
Anger 44.33 23.50 23 6629 12433 63469937
Eye movement disorder 41.97 23.50 17 6635 5211 63477159
Food craving 39.38 23.50 12 6640 1594 63480776
Dystonia 39.34 23.50 22 6630 13797 63468573
Dyskinesia 39.15 23.50 30 6622 31972 63450398
Wrong technique in product usage process 37.30 23.50 39 6613 62301 63420069
Insomnia 36.68 23.50 74 6578 215178 63267192
Parakeratosis 36.49 23.50 8 6644 287 63482083
Psychiatric symptom 35.23 23.50 15 6637 5208 63477162
Product use issue 34.27 23.50 73 6579 220447 63261923
Sedation 34.07 23.50 30 6622 38779 63443591
Blood prolactin increased 33.75 23.50 13 6639 3490 63478880
Compulsive shopping 33.65 23.50 9 6643 750 63481620
Suicidal behaviour 33.53 23.50 12 6640 2627 63479743
Internal haemorrhage 32.10 23.50 14 6638 5151 63477219
Drug effective for unapproved indication 30.70 23.50 12 6640 3352 63479018
Seborrhoeic dermatitis 30.17 23.50 9 6643 1112 63481258
Feeling abnormal 30.15 23.50 55 6597 148337 63334033
Muscle twitching 29.84 23.50 21 6631 19647 63462723
Underdose 29.82 23.50 24 6628 27432 63454938
Hypomania 29.37 23.50 14 6638 6316 63476054
Dissociation 28.72 23.50 11 6641 2908 63479462
Hunger 28.37 23.50 13 6639 5366 63477004
Incorrect dose administered 28.07 23.50 33 6619 59935 63422435
Parkinsonism 28.04 23.50 16 6636 10423 63471947
Binge eating 27.58 23.50 7 6645 475 63481895
Agitation 26.52 23.50 32 6620 59725 63422645
Increased appetite 26.51 23.50 15 6637 9615 63472755
Delusion 25.95 23.50 16 6636 12001 63470369
Treatment noncompliance 25.32 23.50 25 6627 37300 63445070
Gambling disorder 25.02 23.50 8 6644 1244 63481126
Cutaneous T-cell lymphoma 24.26 23.50 8 6644 1372 63480998
Lactation disorder 23.98 23.50 6 6646 384 63481986

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 331.48 37.60 85 2707 8024 34946115
Weight increased 120.91 37.60 81 2711 92952 34861187
Tardive dyskinesia 108.49 37.60 33 2759 5757 34948382
Product use in unapproved indication 82.75 37.60 71 2721 117428 34836711
Hallucination, auditory 71.18 37.60 29 2763 11888 34942251
Product administered to patient of inappropriate age 66.97 37.60 20 2772 3271 34950868
Suicidal ideation 66.72 37.60 41 2751 40347 34913792
Restlessness 63.95 37.60 34 2758 25448 34928691
Anxiety 59.78 37.60 55 2737 99373 34854766
Psychotic disorder 59.60 37.60 32 2760 24420 34929719
Off label use 52.92 37.60 108 2684 419416 34534723
Apathy 48.79 37.60 19 2773 6913 34947226
Loss of libido 45.45 37.60 14 2778 2538 34951601
Inability to afford medication 43.67 37.60 12 2780 1458 34952681
Hypomania 38.06 37.60 12 2780 2347 34951792

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 281.24 24.59 82 5907 13177 79725222
Tardive dyskinesia 281.12 24.59 78 5911 10493 79727906
Product use in unapproved indication 198.76 24.59 158 5831 250201 79488198
Weight increased 170.36 24.59 151 5838 277235 79461164
Hallucination, auditory 168.41 24.59 62 5927 20631 79717768
Product administered to patient of inappropriate age 107.39 24.59 32 5957 5521 79732878
Tremor 97.03 24.59 89 5900 169994 79568405
Suicidal ideation 96.42 24.59 64 5925 76276 79662123
Restlessness 94.85 24.59 53 5936 46439 79691960
Oculogyric crisis 88.70 24.59 24 5965 2928 79735471
Anxiety 72.27 24.59 91 5898 248421 79489978
Off label use 70.11 24.59 186 5803 907029 78831370
Discoloured vomit 68.67 24.59 17 5972 1461 79736938
Dissociation 60.03 24.59 19 5970 4002 79734397
Inability to afford medication 58.07 24.59 17 5972 2756 79735643
Apathy 50.72 24.59 23 5966 12954 79725445
Collagen-vascular disease 48.36 24.59 8 5981 85 79738314
Psychotic disorder 45.78 24.59 32 5957 41370 79697029
Loss of libido 45.58 24.59 14 5975 2671 79735728
Depression 40.08 24.59 64 5925 216726 79521673
Dystonia 39.85 24.59 23 5966 21376 79717023
Neuroleptic malignant syndrome 39.40 24.59 25 5964 27534 79710865
Dyskinesia 39.08 24.59 30 5959 44743 79693656
Anger 38.93 24.59 21 5968 17141 79721258
Delusion 38.16 24.59 22 5967 20401 79717998
Hypomania 38.04 24.59 16 5973 7528 79730871
Insomnia 36.86 24.59 66 5923 245104 79493295
Parakeratosis 36.83 24.59 8 5981 386 79738013
Parkinsonism 36.80 24.59 20 5969 16564 79721835
Psychiatric symptom 35.74 24.59 15 5974 7020 79731379
Treatment noncompliance 34.99 24.59 30 5959 52238 79686161
Schizophrenia 32.55 24.59 18 5971 15422 79722977
Hallucination 32.47 24.59 36 5953 85709 79652690
Suicidal behaviour 31.15 24.59 11 5978 3236 79735163
Underdose 30.66 24.59 23 5966 33128 79705271
No adverse event 30.45 24.59 24 5965 37168 79701231
Persecutory delusion 30.17 24.59 12 5977 4897 79733502
Suicide attempt 30.00 24.59 34 5955 82898 79655501
Internal haemorrhage 29.37 24.59 14 5975 8819 79729580
Sedation 29.20 24.59 27 5962 51868 79686531
Hunger 29.01 24.59 12 5977 5416 79732983
Blood prolactin increased 28.89 24.59 11 5978 4000 79734399
Extrapyramidal disorder 28.55 24.59 19 5970 22660 79715739
Product use issue 28.39 24.59 54 5935 209768 79528631
Feeling abnormal 28.03 24.59 46 5943 159153 79579246
Gambling disorder 27.88 24.59 9 5980 2017 79736382
Seborrhoeic dermatitis 27.68 24.59 9 5980 2064 79736335
Mania 27.19 24.59 17 5972 18243 79720156
Altered state of consciousness 27.01 24.59 24 5965 43798 79694601
Completed suicide 27.00 24.59 58 5931 245709 79492690
Agitation 26.52 24.59 35 5954 99680 79638719
Compulsive shopping 26.23 24.59 7 5982 809 79737590
Wrong technique in product usage process 26.23 24.59 30 5959 73845 79664554
Egocentrism 25.49 24.59 3 5986 0 79738399
Bruxism 25.30 24.59 10 5979 4016 79734383

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AX16 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Other antipsychotics
MeSH PA D015259 Dopamine Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
FDA EPC N0000175430 Atypical Antipsychotic

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419
Major depressive disorder indication 370143000




šŸ¶ Veterinary Drug Use

None

šŸ¶ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.14 acidic
pKa2 8.07 Basic
pKa3 0.9 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.25MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8349840 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.25MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
0.25MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
0.25MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.25MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
0.25MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
0.5MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8349840 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.5MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
0.5MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
0.5MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.5MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
0.5MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
1MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8349840 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
1MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
1MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
1MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
2MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8349840 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
2MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
2MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
2MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
3MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8349840 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
3MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
3MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
3MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
3MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
3MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
4MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8349840 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
4MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
4MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 8618109 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
4MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
4MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA
4MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL 9839637 April 12, 2026 TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.25MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL Dec. 27, 2024 NEW PATIENT POPULATION
0.5MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL Dec. 27, 2024 NEW PATIENT POPULATION
1MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL Dec. 27, 2024 NEW PATIENT POPULATION
2MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL Dec. 27, 2024 NEW PATIENT POPULATION
3MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL Dec. 27, 2024 NEW PATIENT POPULATION
4MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL Dec. 27, 2024 NEW PATIENT POPULATION
0.25MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL May 10, 2026 TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMERā€™S DISEASE
0.5MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL May 10, 2026 TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMERā€™S DISEASE
1MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL May 10, 2026 TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMERā€™S DISEASE
2MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL May 10, 2026 TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMERā€™S DISEASE
3MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL May 10, 2026 TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMERā€™S DISEASE
4MG REXULTI OTSUKA N205422 July 10, 2015 RX TABLET ORAL May 10, 2026 TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMERā€™S DISEASE

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR AGONIST Ki 9.52 SCIENTIFIC LITERATURE DRUG LABEL
5-hydroxytryptamine receptor 1A GPCR AGONIST Ki 9.92 SCIENTIFIC LITERATURE DRUG LABEL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.33 SCIENTIFIC LITERATURE DRUG LABEL
Beta-1 adrenergic receptor GPCR Ki 7.23 SCIENTIFIC LITERATURE
Beta-2 adrenergic receptor GPCR Ki 7.17 SCIENTIFIC LITERATURE
D(1A) dopamine receptor GPCR AGONIST Ki 6.80 SCIENTIFIC LITERATURE
Alpha-2A adrenergic receptor GPCR Ki 7.82 SCIENTIFIC LITERATURE
Sodium-dependent serotonin transporter Transporter INHIBITOR IC50 7.54 SCIENTIFIC LITERATURE
Sodium-dependent noradrenaline transporter Transporter INHIBITOR IC50 6.86 SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 2B GPCR ANTAGONIST Ki 8.72 SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 2C GPCR Ki 7.47 SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 6 GPCR Ki 7.24 SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 8.43 SCIENTIFIC LITERATURE
Alpha-2B adrenergic receptor GPCR Ki 7.77 SCIENTIFIC LITERATURE
D(3) dopamine receptor GPCR AGONIST Ki 8.96 SCIENTIFIC LITERATURE
Histamine H1 receptor GPCR ANTAGONIST Ki 7.72 SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 1B GPCR Ki 7.50 SCIENTIFIC LITERATURE
Alpha-2C adrenergic receptor GPCR ANTAGONIST Ki 9.23 SCIENTIFIC LITERATURE
Sodium-dependent dopamine transporter Transporter INHIBITOR IC50 6.03 SCIENTIFIC LITERATURE
D(4) dopamine receptor GPCR AGONIST Ki 8.20 SCIENTIFIC LITERATURE
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 8.59 SCIENTIFIC LITERATURE
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 9.77 SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 5A GPCR Ki 6.85 SCIENTIFIC LITERATURE
Alpha-1A adrenergic receptor GPCR Ki 8.42 SCIENTIFIC LITERATURE
D(2) dopamine receptor GPCR Ki 9.70 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 10.05 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 8.64 CHEMBL

External reference:

IDSource
D10309 KEGG_DRUG
4034625 VUID
N0000191737 NUI
4034625 VANDF
CHEBI:134716 CHEBI
CHEMBL2105760 ChEMBL_ID
C000591922 MESH_SUPPLEMENTAL_RECORD_UI
7672 IUPHAR_LIGAND_ID
DB09128 DRUGBANK_ID
1658314 RXNORM
234913 MMSL
31120 MMSL
d08373 MMSL
016270 NDDF
716069007 SNOMEDCT_US
781292006 SNOMEDCT_US
C3885614 UMLSCUI
9552 INN_ID
11978813 PUBCHEM_CID
2J3YBM1K8C UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Brexpiprazole Human Prescription Drug Label 1 27241-204 TABLET 0.25 mg ORAL ANDA 32 sections
Brexpiprazole Human Prescription Drug Label 1 27241-205 TABLET 0.50 mg ORAL ANDA 32 sections
Brexpiprazole Human Prescription Drug Label 1 27241-206 TABLET 1 mg ORAL ANDA 32 sections
Brexpiprazole Human Prescription Drug Label 1 27241-207 TABLET 2 mg ORAL ANDA 32 sections
Brexpiprazole Human Prescription Drug Label 1 27241-208 TABLET 3 mg ORAL ANDA 32 sections
Brexpiprazole Human Prescription Drug Label 1 27241-209 TABLET 4 mg ORAL ANDA 32 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-035 TABLET 0.25 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-035 TABLET 0.25 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-035 TABLET 0.25 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-036 TABLET 0.50 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-036 TABLET 0.50 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-036 TABLET 0.50 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-037 TABLET 1 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-037 TABLET 1 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-037 TABLET 1 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-038 TABLET 2 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-038 TABLET 2 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-038 TABLET 2 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-039 TABLET 3 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-039 TABLET 3 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-039 TABLET 3 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-040 TABLET 4 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-040 TABLET 4 mg ORAL NDA 37 sections
Rexulti HUMAN PRESCRIPTION DRUG LABEL 1 59148-040 TABLET 4 mg ORAL NDA 37 sections
brexpiprazole HUMAN PRESCRIPTION DRUG LABEL 1 60219-1649 TABLET, FILM COATED 0.25 mg ORAL ANDA 29 sections
brexpiprazole HUMAN PRESCRIPTION DRUG LABEL 1 60219-1650 TABLET, FILM COATED 0.50 mg ORAL ANDA 29 sections
brexpiprazole HUMAN PRESCRIPTION DRUG LABEL 1 60219-1651 TABLET, FILM COATED 1 mg ORAL ANDA 29 sections
brexpiprazole HUMAN PRESCRIPTION DRUG LABEL 1 60219-1652 TABLET, FILM COATED 2 mg ORAL ANDA 29 sections
brexpiprazole HUMAN PRESCRIPTION DRUG LABEL 1 60219-1653 TABLET, FILM COATED 3 mg ORAL ANDA 29 sections
brexpiprazole HUMAN PRESCRIPTION DRUG LABEL 1 60219-1654 TABLET, FILM COATED 4 mg ORAL ANDA 29 sections